Biobanque Québécoise Pédiatrique de Cancers et de Greffes de cellules hématopoïétiques, Canada
Objective: We have been recruiting childhood Acute Lymphoblastic Leukemia (cALL) patients diagnosed at the Sainte-Justine Hospital since 1994. cALL represents ~25% of all malignant childhood diseases, is the most common pediatric cancer and leading cause of cancer related mortality among children. In our laboratory, translational research is geared toward advancing knowledge across the continuum of pediatric cancer care spanning prevention through diagnosis/prognosis, to long-term survival. Our biobank is a resource that houses clinical data and biological samples from 4 patient-based study cohorts: the Quebec childhood Acute Lymphoblastic Leukemia (QcALL) cohort, patients from the PETALE cALL survivor cohort, patients who underwent bone marrow transplant (BaCH), and patients from the Personalized Targeted Therapy in Refractory/Relapsed Cancer in Childhood (TRICEPS) study. For each QcALL patient, we collect biospecimens at diagnosis, throughout the 2-year treatment course and at relapse or pre-/post-transplant if applicable. The QcALL study is leveraging largescale omic studies geared toward identifying novel (epi)genetic driver events to improve diagnostic and prognostic tools in cALL. Since 2012, we have been recruiting patients with a five-year event-free survival period to participate in the PETALE study aimed at identifying the genomic determinants of common treatment related toxicities in cALL survivors. Since 2014, the BaCH study is interested in hematopoietic cell transplantation to better understand the reconstitution mechanisms and improve the outcomes of various types of transplantation. The TRICEPS study, started in January 2014, involves timely (12-week time frame) indepth characterization of tumor genomes to identify actionable mutations and provide personalized targeted therapy for refractory/relapsed childhood cancer patients. To store patient-related clinical, demographic, and genetic information we developed PANDORA 2.0, a Biobank Software System. This in-house solution aims to cover many of the research and operation activities applicable to biological repositories such as inventory tracking, management of patient consent forms, and report generation. All of the information contained in PANDORA actively contributes to translational research, bringing patients, researchers and oncologists closer, with the ultimate goal of improving present diagnostic and therapeutic strategies while minimising treatment side effects in pediatric cancers.
|Registered Biobank Name||Biobanque Québécoise Pédiatrique de Cancers et de Greffes de cellules hématopoïétiques|
|Biobank Leader||Thomas Sontag|
|Email for biobank email@example.com|
|Principal Investigator||Dr Daniel Sinnett|
||Oligo - Collection aimed at supporting several research projects, a research group or a research consortium|